Acquisitions
1. Senores Pharma acquires from Wockhardt US FDA approved ANDA for epilepsy & migraine drug, topiramate HCl 25, 50, 100 and 200 mg tablets.
2. India based AI-driven genomics and personalized health player MapmyGenome has acquired Canadian microbial sequencing player Microbiome Insights.
3. Strides Pharma has acquired four approved ANDAs for the US market from Nostrum Laboratories.
4. Novartis to acquire Regulus Therapeutics for US$800 million up front with additional payments of US$900 million. The acquisition includes Regulus' lead asset, farabursen, for treating ADPKD.
5. Regeneron to buy DNA testing firm 23andMe for US$256 million.
6. Eli Lilly has announced a definitive agreement to acquire SiteOne Therapeutics, a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders.
Licensing
1. Lupin out-licenses eye disease biosimilar for Latin America rights to SteinCares.
2. Divi's Laboratories inks manufacturing and supply agreement with global pharma company.
3. Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly for ATLX-1282, for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.
4. Pfizer signs licensing deal with China's 3SBio for cancer.
Investment
1. Sun Pharma raises stake to 22.7% in Pharmazz Inc. by investing further US$25 million.
2. Dutch biotech Azafaros concluded an oversubscribed US$147 million (€132-million ) series B round to accelerate the development of its lead asset nizubaglustat for lysosomal storage disorders.
3. TILT Biotherapeutics closes US$25 million Series B Financing to support a Phase 2 clinical trial of Tiltbio’s lead product, TILT-123.
Co-development
1. Shionogi has entered into a joint research agreement with Cilcare for the creation of a new drug pipeline for hearing loss.
2. Roche’s Genentech partnered with Repertoire Immune Medicines on a deal worth up to US$765 million to develop T-cell-targeted treatments for autoimmune diseases.
3. Tempus AI signed a US$200 million deal with AstraZeneca and Pathos AI to develop a multimodal foundation model for oncology to gather biological and clinical insights
4. Recipharm enters strategic partnership with ProductLife Group.
5. Bristol Myers to pay US$1.5 billion upfront for BioNTech cancer drug BNT327, for multiple solid tumor types.
Aagami Updates:
1. New Client Win: Michigan company Improving cancer survival using smart targeted drug delivery.
2. New Client Win: Biopharma company Uncoupling Metastasis and Proliferation with translational platform,using machine learning and known molecules to disrupt cancer treatment and stopping proliferation.
3. Aagami to attend BIO International Convention in Boston (June 16-19). Our Calendar is getting full. Please send us your meeting requests at the earliest.
4. Aagami Research Team (ART) has prepared a report , highlighting select cross border deals of Indian companies covering Jan 2023 – Mar 2025.
a. The deals reveal robust activity across acquisitions, investments, licensing, and strategic collaborations, highlighting India’s expanding global footprint.
b. If you would like to receive a complimentary copy of the report, please contact us.
5. Aagami CEO Dinesh Jain has been chosen to moderate Session 2 of INDIA UNLIMITED 3.0 - Collaborate, Invest, Outsource (A BIO 2025 Affiliate event) on Sunday June 15 from 2pm to 5pm at Hyatt Regency Boston on Lafayette Avenue.
a. Session 1: India’s growing global footprint and prowess in Biologics.
b. Session 2: Servicing global research, discovery, development and manufacturing requirements.
Select opportunities available with us:
For Partnering/Licensing/ Co-development:
1. Seeking Co-development Partner/Investor/EPO supplier for Phase 3 stage Erythropoietin (EPO) patented asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). By using the 351(A) dossier, an easy and quick path via 351 (K) Biosimilar approval for multiple indications may also be obtained.
2. Seeking Co-development/Out-Licensing: Phase 3 stage small molecule first-in-class eye drop to treat pre-surgical cataract (typically for patients under 72 years of age).
3. Seeking Licensing/Partnering: Phase 2 Drug poised to revolutionize antiviral treatment; could be a single drug to treat all the "tripledemic" viruses (RSV, FLU, COVID). Also, Phase 2 trials are starting in Central Africa for MPOX. Very effective in Bird Flu and Measles too.
For Acquisition:
1. Lucrative Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic.
2. Available at a very reasonable price Mountain View Pharma (MVP) including its PharmaPEG® technology, product candidates, data package of ~20 drug candidates, IP etc.- for Next-generation biologics.
3. Asset sale - US client’s Smart Drug preventing Myelodysplastic Syndromes (MDS) from advancing to full-scale myelogenous Leukemia (Second Human Trial of 30 patients ongoing in AU). Now Leveraging the Latest in AI.
Seeking Investment:
1. High ROI Opportunity to Invest in U.S.based medtech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform (On the market). With over US $60 Million raised, our client is offering special terms to invest in current B-4/B-5 round. Expected ROI is 2-4x in 12-18 months via an IPO, strategic M&A, or private equity buyout.
Specialized Services
1. Specialist CDMO of Oligonucleotides and peptides from Japan for one stop solution to accelerate R&D and Kilo Scale manufacturing. 40+ PhDs, Best in quality, excellent customer service and reasonable cost.
Hope you found the content useful. We welcome your feedback and queries.